MAP
AKRO

Moody Aldrich Partners’s Akero Therapeutics AKRO Stock Holding History

Moody Aldrich Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,994
Closed -$1.1M – 155
2022
Q4 		$1.1M Buy
+19,994
New +$857K 0.22% 114

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Moody Aldrich Partners's AKRO Position: Q1 2023 in Review

Moody Aldrich Partners sold out of Akero Therapeutics (AKRO) in Q1 2023, closing a stake of 19,994 shares — an estimated $1.1M sold.

Moody Aldrich Partners first reported a position in AKRO in Q4 2022 and held it in 1 quarter. The position peaked at $1.1M in Q4 2022. 156 funds tracked by Wall St. Rank hold AKRO as of Q1 2023.

  • Moody Aldrich Partners reported no remaining Akero Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Moody Aldrich Partners sold 19,994 Akero Therapeutics shares in Q1 2023, an estimated $1.1M.
  • Moody Aldrich Partners first reported a position in Akero Therapeutics in Q4 2022 and held it in 1 quarter.
  • Moody Aldrich Partners's Akero Therapeutics position peaked at $1.1M in Q4 2022.
  • 156 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2023.

Based on Moody Aldrich Partners's 13F filing for Q1 2023, filed 27 Apr 2023.